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ABSTRACT
Objectives Patients with rheumatoid arthritis (RA) are
at increased risk of myocardial infarction (MI) compared
with subjects without RA, with the increased risk driven
potentially by inﬂammation. Tumour necrosis factor
inhibitors (TNFi) may modulate the risk and severity of
MI. We compared the risk and severity of MI in patients
treated with TNFi with that in those receiving synthetic
disease-modifying antirheumatic drugs (sDMARDs).
Methods This analysis included patients with RA
recruited from 2001 to 2009 to the British Society for
Rheumatology Biologics Register for Rheumatoid Arthritis
starting TNFi (etanercept/inﬂiximab/adalimumab) and a
biologic-naïve comparator cohort receiving sDMARD. All
patients were followed via physician and patient
questionnaires and national death register linkage.
Additionally, all patients were linked to the Myocardial
Ischaemia National Audit Project, a national registry of
hospitalisations for MI. Patients were censored at ﬁrst
veriﬁed MI, death, 90 days following TNFi
discontinuation, last physician follow-up or 20 April
2010, whichever came ﬁrst. The risk of ﬁrst MI was
compared between cohorts using COX regression,
adjusted with propensity score deciles (PD). MI
phenotype and severity were compared using descriptive
statistics. 6-month mortality post MI was compared
using logistic regression.
Results 252 veriﬁed ﬁrst MIs were analysed: 58 in
3058 patients receiving sDMARD and 194 in 11 200
patients receiving TNFi (median follow-up per person
3.5 years and 5.3 years, respectively). The PD-adjusted
HR of MI in TNFi referent to sDMARD was 0.61 (95% CI
0.41 to 0.89). No statistically signiﬁcant differences in
MI severity or mortality were observed between
treatment groups.
Conclusions Patients with RA receiving TNFi had a
decreased risk of MI compared with patients with RA
receiving sDMARD therapy over the medium term. This
might be attributed to a direct action of TNFi on the
atherosclerotic process or better overall disease control.
INTRODUCTION
In meta-analyses, patients with rheumatoid arthritis
(RA) have a 60% increased risk of myocardial infarc-
tion (MI) and a 70% increased risk in mortality from
MI compared with the general population.1 2 As the
development of atherosclerosis in the general popula-
tion is viewed as an inﬂammatory process, it is pos-
sible that the chronic inﬂammation associated with RA
may accelerate this. Traditional cardiovascular (CV)
risk factors do not fully explain the increased risk of
MI associated with RA.3–5 Drugs inhibiting tumour
necrosis factor α (TNFi) have been shown to reduce
joint inﬂammation and associated inﬂammatory
markers; thus, they may also inﬂuence the future risk
of MI.
The association between TNFi exposure and MI
risk has been investigated previously in patients with
RA. Some studies found a reduced risk, but others a
similar risk compared with treatment with
synthetic disease-modifying antirheumatic drugs
(sDMARDs).6–15 Most of these studies only fol-
lowed patients for 1–2 years. TNFi may inﬂuence
the incidence of MI in the short term by stabilising
plaque. However, any effect on plaque formation is
likely to take much longer. Therefore, the full
inﬂuence of TNFi on future MI risk may take
many years to become apparent.16 Also, as MI is a
relatively uncommon event, large sample sizes are
required to assess this risk.
As well as inﬂuencing the occurrence of MI,
tumour necrosis factor α (TNFα) may affect the
outcome after a CV event. TNFα appears to limit
infarct size by preventing or delaying apoptosis of
cardiac myocytes and may have a homeostatic role
in limiting the amount and duration of damage
after an ischaemic insult.17 Conversely, neutralising
TNFα with antibodies has been shown to reduce
infarct size in murine models.18 The outcome of
MI in patients with RA receiving TNFi therapy has
not previously been studied.
We aimed to compare (1) the incidence of MI
over the medium term, (2) the severity of MI and
(3) the mortality post MI between patients with RA
treated with TNFi therapy and those treated with
sDMARD therapy.
METHODS
Study design and setting
The British Society for Rheumatology Biologics
Register for Rheumatoid Arthritis (BSRBR-RA) is a
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UK-wide prospective observational study, established in 2001 to
monitor the long-term safety of TNFi and other biological ther-
apies.19 UK guidelines restrict the prescription of TNFi in RA to
patients with (i) sustained active disease (28-joint disease activity
score (DAS28) >5.1 on at least two occasions a month apart)
and (ii) who have failed to respond to therapeutic doses of ≥2
sDMARDs (including methotrexate, unless contraindicated)
given for ≥6 months.20 The TNFi-treated patients included in
this analysis were recruited between 2001 and 2005 (etaner-
cept), 2001 and 2008 (inﬂiximab) and 2004 and 2008 (adalimu-
mab). Recruitment to each TNFi drug continued from when
that TNFi was licensed in UK until the target of 4000 patients
per TNFi was reached. We recruited a comparator cohort of
biologic-naïve patients with active disease (guide DAS28>4.2)
receiving sDMARD therapies only, between 2002 and 2009. If
patients in the comparator cohort were switched to TNFi
therapy, they were given the option to re-consent to recruitment
to the TNFi cohort (if recruitment to that TNFi cohort was still
open); otherwise follow-up was discontinued. Patients could not
switch from the TNFi cohort to the sDMARD cohort.
Both cohorts were followed identically via physician and
patient questionnaires. Questionnaires were sent to the rheuma-
tology team every 6 months for the ﬁrst 3 years of follow-up
and annually thereafter, regardless of changes to therapy,
requesting information on disease details, medication and
comorbidities, as well as the occurrence of adverse events. At
baseline, physicians were asked if the patient had a history of
MI or angina. Patients provided information on hospitalisations
via questionnaires every 6 months for the ﬁrst 3 years of
follow-up. For all reports of MI, additional clinical data (dis-
charge summaries, ECG, cardiac enzymes, pathology reports)
were requested to aid event veriﬁcation and classiﬁcation. All
patients were ﬂagged with the Health and Social Care
Information Centre for reporting of deaths. Causes of death
(COD) were coded from the death certiﬁcate using the
International Classiﬁcation of Diseases 10.
In addition, the BSRBR-RA dataset was linked to the
Myocardial Ischaemia National Audit Project (MINAP).
Established in 1999, MINAP audits the care and outcome of all
patients admitted to an acute National Health Service (NHS)
hospital in England or Wales with a suspected MI against
national standards.21 MINAP collects patient-level information
including patient demographics, dates of admission, MI pheno-
type, baseline risk, comorbidities, investigations, details of reper-
fusion therapy, in-hospital drug treatment, clinical complications
and all-cause mortality.
The BSRBR-RA and MINAP datasets were linked using deter-
ministic matching based on surname, forename, gender, unique
NHS number, date of birth and postcode. The matching strategy
used a maximum of four linkage variables in any one combin-
ation. MINAP events which matched to a BSRBR-RA patient
were returned to the BSRBR-RA for analysis.
Participants
This analysis included all patients with a physician diagnosis of
RA starting etanercept, inﬂiximab or adalimumab as their ﬁrst
biologic within 6 months of registration with BSRBR-RA, or
registered into the sDMARD cohort (ﬁgure 1). The analysis was
limited to patients with at least moderate disease activity at the
start of therapy (DAS28≥3.2) and with no past history of MI or
angina. All patients had to have at least one returned rheumatol-
ogy team follow-up questionnaire to conﬁrm treatment start.
Written consent was obtained from all patients according to the
Declaration of Helsinki. Approval for the BSRBR-RAwas given by
the North West Multicentre Research Ethics Committee (reference
no: 00/8/53). The National Institute for Cardiovascular Outcomes
Research (NICOR) which includes MINAP (Ref: NIGB: ECC
1-06 (d)/2011) has support under Section 251 of the NHS Act
2006 to use patient information for medical research without
requiring additional consent. The data linkage in this analysis was
approved by the MINAPAcademic Group.
Veriﬁcation of MI
All potential MIs reported to BSRBR-RA, MINAP or both were
veriﬁed using the American Heart Association/European Society
Figure 1 Patient selection for analysis. BSRBR-RA, British Society for
Rheumatology Biologics Register for Rheumatoid Arthritis; DAS28,
disease activity in 28 joints; DMARD, disease-modifying antirheumatic
drug; MI, myocardial infarction; RA, rheumatoid arthritis; TNF, tumour
necrosis factor.
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of Cardiology (AHA/ESC) criteria for MI.22 If a reported event
could not be veriﬁed against the AHA/ESC criteria for MI, but
the patient received thrombolysis or primary angioplasty or died
with MI recorded as the underlying COD, this was also consid-
ered to be a veriﬁed MI.
Drug exposure models and statistical methods
The primary event was the ﬁrst veriﬁed MI for each patient.
Crude incidence rates of ﬁrst MI with 95% CIs were calculated
using a Poisson distribution. For the TNFi cohort, follow-up
started on the ﬁrst day of treatment. For the sDMARD cohort,
follow-up started on the date of registration. MIs were attribu-
ted to TNFi therapy if they occurred on drug or within 90 days
of drug discontinuation. Follow-up was censored at ﬁrst veriﬁed
MI, death, date of last physician follow-up or 20 April 2010,
whichever came ﬁrst. The risk of ﬁrst MI was compared
between TNFi-treated and sDMARD-treated patients using a
COX proportional hazards model, adjusted for deciles of pro-
pensity score (PD). This was presented using HRs with 95% CI.
Sensitivity analyses included (1) analysing the data using an ever-
exposed drug model (ie, all exposure time following ﬁrst dose
of TNFi) and (2) trimming of the PD at 5%.
Baseline confounders were speciﬁed a priori and entered into
a logistic regression model to generate a PD, reﬂecting the likeli-
hood of receiving TNFi depending on covariates. These covari-
ates were age, gender, DAS28, disease duration, health
assessment questionnaire score, whether the patient had used
≥4 sDMARDs prior to study registration, whether the patient
was recruited to the register before 30 June 2004 (the approxi-
mate midpoint of study recruitment, chosen to account for tem-
poral changes in baseline disease severity over time),23
hypertension, diabetes, chronic lung disease, smoking (ever/
never), antiplatelet therapy, non-steroidal anti-inﬂammatory
drugs (NSAID)/cyclooxygenase inhibitor (COX)-2 inhibitor use,
glucocorticoid use and statin use. Missing data were imputed by
multiple imputation by chained equations (MICE).24 The imput-
ation model included whether the patient experienced an MI,
logarithm of the time to MI and the other covariates as
described25 (see online supplementary web appendix).
Severity of the MI was deﬁned according to (1) MI pheno-
type: ST elevation versus non-ST elevation (STEMI vs
NSTEMI), (2) presence or absence of cardiac arrest during hos-
pital admission, (3) peak creatine kinase (CK), peak troponin I,
peak troponin T and (4) length of hospital stay. These para-
meters were compared between cohorts using the χ2 test for cat-
egorical variables and the Wilcoxon rank-sum test for
continuous variables. This analysis was limited to those MIs cap-
tured in the MINAP registry. For this analysis, patients were
divided into three groups based on treatment at the time of
their MI: Group 1 (sDMARD) (referent), Group 2 (receiving
TNFi therapy at the time of or within 90 days prior to the MI)
and Group 3 (exposed to TNFi but outside the 90-day lag
window prior to the MI).
Mortality post MI was deﬁned as any death that occurred
within 6 months following the initial MI. The results are pre-
sented for (1) all MIs irrespective of reporting source and (2)
for those MIs with additional data from MINAP. Using logistic
regression, the risk of death within 6 months post MI was com-
pared between the three groups, with the sDMARD group as
the referent. For all MIs, mortality was adjusted for age and
gender. For those MIs with additional data from MINAP, the
analysis was adjusted for age, gender and the Modiﬁed Global
Registry of Acute Coronary Events (MG) score: a composite
score including age, heart rate, systolic blood pressure,
creatinine, cardiac arrest at admission, ST segment deviation,
elevated cardiac enzymes and loop diuretic use at admission.26 27
Higher scores indicate a higher probability of death (range: 0–
274). Missing data for components of MG were replaced using
multiple imputation.28 The risk of death was estimated using
logistic regression. ORs with 95% CI were presented. All ana-
lyses were performed using Stata V.13 (StataCorp, College
Station, Texas, USA).
RESULTS
Baseline characteristics
A total of 14 258 patients (sDMARD: 3058, TNFi: 11 200)
were analysed (table 1 and ﬁgure 1). At baseline, the TNFi
cohort was younger, comprised of proportionally more females,
had longer disease duration and higher disease activity and func-
tional disability compared with the sDMARD cohort. Patients in
the TNFi cohort were also more likely to receive glucocorticoids
and NSAID/COX-2 inhibitors, but were less likely to be on anti-
platelet drugs and statins. Patients in the TNFi cohort also had a
lower frequency of smoking, hypertension and diabetes com-
pared with the sDMARD cohort. Median duration of exposure
to TNFi was 4.1 years (IQR 2.0, 5.8).
Risk of MI in TNFi-treated patients compared with
sDMARD-treated patients
There were 58 veriﬁed ﬁrst MIs during a median of 3.5 years
follow-up in the sDMARD cohort (total follow-up 10 337 -
person-years (pyrs)) and 194 MIs during a median of 5.3 years
follow-up in the TNFi cohort (total follow-up 55 636 pyrs)
(table 2). The crude incidence rate of ﬁrst MIs per 10 000 pyrs
was 56 (95% CI 46 to 73) in the sDMARD cohort and 35
(95% CI 30 to 40) in the TNFi cohort. The median time to ﬁrst
MI was 1.56 years (IQR 0.89, 3.43) in the sDMARD cohort
and 2.43 years (IQR 1.41, 3.96) in the TNFi cohort.
Table 1 Baseline characteristics of patients in sDMARD and TNFi
cohorts
sDMARD;
n=3058
TNFi;
n=11 200
Mean age, years (SD) 59.5 (12.5) 55.6 (12.3)
Female, % 75 78
Median disease duration, years (IQR) 6 (1, 15) 11 (6, 19)
Mean DAS28 (SD) 5.3 (1.1) 6.6 (1.0)
Mean HAQ score (SD) 1.5 (0.7) 2.0 (0.6)
Proportion of patients who received ≥4
sDMARDs prior to study registration, %
21 53
Proportion of patients who received
methotrexate prior to study registration, %
82 97
Recruited before 30 June 2004, % 19 51
Hypertension, % 30 28
Diabetes, % 6 5
Chronic lung disease, % 19 13
Current/previous smoker, % 62 59
Glucocorticoid, % 22 44
NSAID/COX-2 inhibitor therapy, % 56 63
Antiplatelet therapy, % 7 5
Statin therapy, % 9 5
COX, cyclooxygenase inhibitor; DAS28, disease activity in 28 joints; HAQ score, health
assessment questionnaire score; NSAID, non-steroidal anti-inflammatory drugs;
sDMARD, synthetic disease-modifying antirheumatic drug; TNFi, tumour necrosis factor
α inhibitor.
Low ASL, et al. Ann Rheum Dis 2017;0:1–7. doi:10.1136/annrheumdis-2016-209784 3
Clinical and epidemiological research
Compared with the sDMARD cohort, the unadjusted HR of
MI in the TNFi cohort was 0.78 (95% CI 0.58 to 1.05). After
adjustment using PD, the risk of MI in the TNFi cohort was
0.61 (95% CI 0.41 to 0.89), indicating a 39% decreased risk of
MI, compared with the sDMARD cohort. There were 276
veriﬁed MIs in the group who were ever exposed to TNF (ie,
when all person-time following ﬁrst dose of TNFi was
included). Adjustment using PD showed a result similar to the
primary model: HR 0.67 (95% CI 0.46 to 0.96) (table 2).
Similar results were also found when propensity scores were
trimmed at 5% (table 2).
Severity of MI
Of the 334 veriﬁed ﬁrst MIs (sDMARD: 58, ever exposed to
TNFi: 276), 136 MIs were captured by BSRBR-RA only, 78
were captured by MINAP only and 120 were captured in both
datasets. There were no signiﬁcant differences (data not shown)
in the age, gender or the proportion of patients receiving TNFi
therapy in those MIs with MINAP data and those without.
Of the 198 MI patients with MINAP data (59%), 35 were
biologic-naïve (Group 1), 108 were receiving TNFi therapy at
the time of or within 90 days prior to the MI (Group 2) and
55 had prior exposure to TNFi (Group 3) (table 3). Overall,
there were no statistically signiﬁcant differences in markers of
severity between the three groups, although there was a trend
towards higher peak CK in patients on TNFi at the time of MI
(table 3).
Post-MI mortality
Of the 334 patients with ﬁrst MIs, 77 (23%) died within
6 months of their MI: 12 (21%) in Group 1, 25 (13%) in
Group 2 and 40 (48%) in Group 3 (exposed, but had stopped
TNFi >90 days before their MI) (table 4). Compared with the
sDMARD-treated group (Group 1), the age and gender adjusted
OR of death in Group 2 was 0.68 (95% CI 0.31 to 1.47) and
that in Group 3 was 3.07 (95% CI 1.42 to 6.62). The median
time between stopping the TNFi and MI occurrence was
1.3 years (IQR 0.5, 2.5). Similar trends in mortality risk were
observed in the subset of MIs captured by MINAP, but there
were very few events, and precision was low (table 4). The
median MG scores were similar between the three groups (108
vs 100 vs 112, respectively). The MG score was a signiﬁcant
univariate predictor of 6-month mortality: OR 1.05 (95% CI
1.02 to 1.07) within these subjects.
DISCUSSION
Previous reports of the association between TNFi therapy and
the risk of MI have only followed patients up to 1–2 years and
have not had consistent ﬁndings. We examined the association
between TNFi therapy and the risk of MI over the medium
term (median follow-up, 5 years) and used propensity scores to
balance differences across a wide range of measured covariates.
A 39% reduction in the risk of MI was observed in patients
treated with TNFi compared with those on sDMARD therapy.
We also report, for the ﬁrst time, the relationship between seve-
rity of and mortality post MI among patients who have received
TNFi therapy.
There is a signal that duration of TNFi exposure is related to
a reduction in cardiovascular disease (CVD) risk in patients with
RA. Bili et al13 found that use of TNFi for more than the
median of 16 months was associated with lower risk of CV
events: relative risk 0.31 (95% CI 0.15 to 0.65). In a Swedish
study, 2 years follow-up on TNFi was associated with a 32%
Table 2 Risk of MI compared between sDMARD and TNFi cohorts
sDMARD;
n=3058 TNFi; n=11 200
Median duration of follow-up per patient,
years (IQR)
3.5 (1.8, 4.9) 5.3 (3.6, 6.4)
Total person-years of exposure, pyrs 10 337 55 636
Primary drug exposure model: on-TNFi+90 days
Number of verified first MIs 58 194
Crude incidence rate of verified first MI
per 10 000 pyrs (95% CI)
56 (43 to 73) 35 (30 to 40)
Unadjusted HR (95% CI) Referent 0.78 (0.58 to 1.05)
HR adjusted for age and
gender (95% CI)
1.19 (0.89 to 1.59)
HR after adjusting for PD* (95% CI) 0.61 (0.41 to 0.89)
Sensitivity analyses
In subjects ever exposed to TNFi;
PD-adjusted HR (95% CI)
0.67 (0.46 to 0.96)
Trimming the PD at 5%; PD-adjusted
HR (95% CI)
0.56 (0.34 to 0.93)
*Deciles of propensity score (PD). The PD included age, gender, DAS28, disease
duration, health assessment questionnaire score, whether the patients used four or
more sDMARDs prior to study registration (yes/no), whether the patients were recruited
to the register before or after 30 June 2004, hypertension, diabetes, chronic lung
disease, smoking (ever/never), antiplatelet therapy, NSAID/COX-2 inhibitor use,
glucocorticoid use and statin use.
COX, cyclooxygenase inhibitor; DAS28, disease activity in 28 joints; MI, myocardial
infarction; NSAID, non-steroidal anti-inflammatory drugs; sDMARD, synthetic
disease-modifying antirheumatic drug; TNFi, tumour necrosis factor α inhibitor.
Table 3 Severity of MI compared between sDMARD and TNFi cohorts
Number of verified first MIs with
additional MINAP data
Group 1 (sDMARD),
n=35
Group 2 (on TNFi at the time of or within
90 days prior to MI), n=108
Group 3 (exposure to TNFi more than
90 days prior to MI), n=55 p Value
Proportion of patients with STEMI, n
(%)
16 (46) 53 (49) 27 (49) 0.32
Cardiac arrest, n (%) 3 (9) 5 (5) 5 (9) 0.48
Median peak CK, IU/L (IQR) 290 (172, 1598) 691 (150, 1293) 286 (125, 660) 0.19
Median peak troponin I, μg/L (IQR) 5.0 (1.3, 7.2) 7.4 (1.1, 22.8) 7.6 (1.5, 29.0) 0.46
Median peak troponin T, μg/L (IQR) 0.7 (0.3, 2.3) 0.9 (0.2, 2.3) 0.8 (0.2, 2.1) 0.95
Median length of hospital stay, days
(IQR)
6 (5, 9) 6 (4, 8) 6 (4, 11) 0.46
CK, creatine kinase; MI, myocardial infarction; MINAP, Myocardial Ischaemia National Audit Project; sDMARD, synthetic disease modifying anti-rheumatic drug; STEMI, ST-elevation
myocardial infarction; TNFi, tumour necrosis factor α inhibitor.
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reduction in the risk of acute coronary syndrome: HR 0.78
(95% CI 0.61 to 1.01).29 There is a biologically plausible
explanation for our ﬁndings as TNFα plays a key role in the
pathogenesis of atherosclerosis.30 Inﬂammation is central in all
stages of atherosclerosis, including endothelial function, plaque
stabilisation and postinfarct remodelling, and thus inhibition of
TNFα may inﬂuence accumulation and progression of plaque
leading to fewer MIs. TNFi may also affect CVD risk via
changes in lipid proﬁle, insulin resistance and diabetes risk.31 32
It is possible that our study ﬁndings are attributable to sup-
pression of inﬂammation and disease control in general rather
than a TNFα-speciﬁc effect. Solomon et al33 observed that
disease activity control was associated with fewer CV events.
Therefore, the current treat-to-target strategy to lower disease
activity in RA may improve pain and function, and also reduce
CV risk either through using sDMARDs or biologics or a com-
bination. In our study, disease activity in the comparator cohort
may have been suppressed by sDMARD therapy, but to a lesser
extent, than in the TNFi cohort, thereby ‘maintaining’ the
already increased background MI risk.
Blockade of TNFα may modify the incidence of MI and inﬂu-
ence the severity and mortality post MI via postinfarct remodel-
ling.17 18 This relationship has not previously been explored
because the relevant data are generally not collected within drug
registries. For this study, we linked with a national MI database
to gain additional data on the MIs. Due to differences in study
design and geographical setting between MINAP and
BSRBR-RA, the overlap of events was not 100%. However,
there were no systematic differences between those with
MINAP data and those without. Overall, there were no differ-
ences in MI severity between treatment groups using indirect
measures (MI phenotype, in-hospital cardiac arrest, troponin
levels and length of hospital stay). We observed a trend towards
higher peak CK levels in patients on TNFi at the time of MI.
However, data on the precise time from MI symptom onset to
measurement of cardiac enzymes in relation to reperfusion treat-
ment were not recorded in MINAP. These parameters may inﬂu-
ence our results; thus, this ﬁnding should be interpreted with
caution.
Mortality post MI in the general population is associated with
a number of factors (eg, age, gender, severity of MI, comorbid-
ities). We were able to use data from MINAP to calculate the
modiﬁed GRACE score and include this in the regression
model. However, small numbers of events precluded robust con-
clusions. We observed a difference in the direction of relative
risk between the group of patients receiving TNFi at the time of
MI and those with prior exposure to TNFi (50% reduction vs
ﬁvefold increase, respectively). In the latter group, the median
time between stopping the TNFi and MI was 1.3 years. Most
patients in the latter group had discontinued their TNFi follow-
ing an adverse event (MI was not the adverse event), which may
imply higher levels of comorbidity in these patients.
This study has several strengths. The prospective design of the
BSRBR-RA, detailed data collection and the size of the study
population meant that it was possible to adjust for a large number
of potential confounders compared with previous publications.
Despite the large range of covariates, we were unable to adjust for
unmeasured confounders such as cumulative steroid dose.
Confounding by indication is an issue with observational
studies. If patients with severe active RA are at increased risk of
CVD and are also more likely to receive TNFi, one would have
expected an increased MI risk in the TNFi group, but instead a
reduced risk was observed. Employment of propensity scores to
balance confounders is an emerging technique in the ﬁeld of phar-
macoepidemiology. In this analysis, the use of PD to adjust for
known confounders was associated with low levels of expected
bias (<5%, see online supplementary web appendix). Linkage
with MINAP enabled analysis of MI severity, including adjustment
by the modiﬁed GRACE score (a risk prediction score for
MI-related death). This study, which has looked at the effects of
TNFi when added to sDMARD therapy, cannot be used to
compare the risk of MI between incident TNFi use and incident
sDMARD use.
In conclusion, treatment with TNFi therapy for RA was asso-
ciated with a reduced risk of MI over the medium term com-
pared with sDMARD therapy. This might be attributed to a
direct action of TNFi on the atherosclerotic process or better
overall disease control or both. Severity of MI and mortality
post MI were not associated with TNFi therapy in our dataset,
but warrants further exploration in collaborative analyses across
other biologic registers.
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Table 4 Mortality within the 6-months following MI
Group 1 (sDMARD)
Group 2 (on TNFi+90 days
lag at time of MI)
Group 3 (exposure to TNFi more
than 90 days prior to MI)
Total number of verified first MIs identified from BSRBR-RA and/or MINAP 58 194 82
Deaths within 6 months, n (%) 12 (21) 25 (13) 40 (48)
Unadjusted OR (95% CI) Referent 0.61 (0.28 to 1.31) 2.84 (1.33 to 6.04)
OR adjusted for age and gender (95% CI) 0.68 (0.31 to 1.47) 3.07 (1.42 to 6.62)
Number of verified first MIs with MINAP data (% total verified MIs) 35 (60) 108 (56) 55 (67)
Deaths within 6 months, n (%) 2 (6) 3 (3) 11 (20)
Median MG score (IQR) 108 (81 to 131) 100 (84 to 120) 112 (93 to 129)
Unadjusted OR (95% CI) Referent 0.47 (0.08 to 2.94) 4.13 (0.86 to 19.89)
OR adjusted for age and gender (95% CI) 0.51 (0.08 to 3.21) 4.07 (0.82 to 20.07)
OR adjusted for MG score (95% CI) 0.47 (0.06 to 3.45) 5.40 (0.93 to 31.18)
BSRBR-RA, British Society for Rheumatology Biologics Register for Rheumatoid Arthritis; MG score, modified Global Registry of Acute Coronary Events score; MI, myocardial infarction;
MINAP, Myocardial Ischaemia National Audit Project; sDMARD, synthetic disease modifying anti-rheumatic drug; TNFi, tumour necrosis factor α inhibitor.
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